The medication being recalled is telmisartan and amlodipine in 40-milligram and 5-milligram doses, respectively. Both medications were distributed in 30-count bottles from Mylan Pharmaceuticals Inc.

A Connecticut federal judge carved a different path Friday for two later generic-drug price-fixing cases from state attorneys general, allowing Mylan executives to revoke their previous invocation of ...

Dr. Kiran Kota joins Intas Pharmaceuticals as VP – API Quality, bringing 25+ years of experience in pharmaceutical quality ...

The Attorney General's Office says Mylan violated state antitrust and consumer protection laws and will provide Connecticut ...

Connecticut officials announced the settlement with Mylan on Thursday. It resolves allegations that the pharmaceutical ...

Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer ...

The State of Connecticut has settled an $8 million lawsuit with pharmaceutical company Mylan over allegations the company illegally inflated EpiPen prices, Attorney General ...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris ...

Vitaris is recalling tablets of its generic telmisartan and amlodipine, in 40-milligram and 5-milligram doses.

Actavis, Aurobindo Pharma, Mallinckrodt, Mylan, Perrigo, Taro Pharmaceuticals, and plaintiff US states filed their joint trial memorandum in a case accusing the companies of conspiring to artificially ...

Viatris has rebounded 50% YTD, driven by a return to growth and operating leverage after years of stagnation and execution issues. I rate the VTRS stock a hold.